Heterogeneity of symptomatology, size, location, number, and biology of leiomyomas is increasingly leading to different treatments for symptomatic women.
From the Center for Uterine Fibroids Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota.
Supported by RC1HD063312 and R01HD060503 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health and NIH/NCRR CTSA Grant No. UL1 RR024150. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.
Corresponding author: Elizabeth A. Stewart, MD, Center for Uterine Fibroids Department of Obstetrics and Gynecology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55901; e-mail: email@example.com.
Financial Disclosure Dr. Stewart has been a Clinical Trial Investigator for Insightec, a consultant to Abbott and Gynesonics, and has served on the scientific advisory board for the Bayer HealthCare Scientific Committee. Dr. Laughlin did not report any potential conflicts of interest.